COMMUNIQUÉS West-GlobeNewswire

Altimmune to Announce First Quarter 2019 Financial Results on May 15

08/05/2019 - 14:00

GAITHERSBURG, Md., May 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March [...]

Allena Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

08/05/2019 - 14:00

-- Entered into Agreement with Duke Clinical Research Institute (DCRI) to Support Phase 3 URIROX-2™ Trial and Promote Enteric Hyperoxaluria Disease Awareness – -- All Clinical Programs Progressing on Track; Expect to [...]

BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transseptal Access to Heart

08/05/2019 - 14:00

SAN CARLOS, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced U.S. Food and Drug [...]

Kura Oncology to Present at Bank of America Merrill Lynch Health Care Conference

08/05/2019 - 14:00

SAN DIEGO, May 08, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson [...]

Progressive Care to Host Conference Call on the 2019 Quarterly Filing and Business Update on May 15th, 2019

08/05/2019 - 14:00

MIAMI, May 08, 2019 (GLOBE NEWSWIRE) -- Progressive Care Inc. ( OTCQB: RXMD ), a personalized healthcare services and technology company, is pleased to announce that the Company has scheduled an investor conference call [...]

Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research

08/05/2019 - 14:00

SAN DIEGO, May 08, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel progesterone [...]

CymaBay Therapeutics Announces Multiple Presentations at DDW 2019

08/05/2019 - 14:00

NEWARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple abstracts related to its seladelpar clinical development program for the treatment of primary [...]

PSIQ to Acquire 80% of Ecoland Including Multiple Cannabis Licenses, Operations and Real Estate for Approximately $18,300,000

08/05/2019 - 14:00

SUNRISE, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- Profile Solutions, Inc. (OTC Pink: PSIQ) is pleased to announce the proposed acquisition of 80% of the Capital Stock and Assets of Ecoland K.K.L. LTD, an Israel LTD. and [...]

C-RAD AB – Interim report January-March 2019

08/05/2019 - 08:30

C-RAD AB – Interim report January-March 2019 REVENUE INCREASE OF 40 PERCENT JANUARY - MARCH 2019 Revenues: 47.3 (33.8) MSEK Order intake: 47.8 (50.6) MSEK EBITDA: 3.6 (-3.6) MSEK Operating profit: 1.2 (-4.7) MSEK Net [...]

Oxurion NV : Oxurion NV Business Update - Q1 2019

08/05/2019 - 07:30

Oxurion NV Business Update - Q1 2019 Significant Progress with Novel Clinical Diabetic Eye Disease Portfolio Enrollment of THR-317 Phase 2 Combination Study & THR-149 Phase 1 Study Completed Ahead of Schedule First [...]

PCI Biotech: First quarter 2019 results

08/05/2019 - 07:30

Oslo (Norway), 8 May 2019 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its first quarter 2019 result. Please find enclosed the report and presentation. First sites for the [...]

Double-digit growth for all strategic brands and DKK 4,234 million in revenue and DKK 1,200 million in EBIT

08/05/2019 - 07:24

HIGHLIGHTS Revenue reached DKK 4,234 million in the first quarter of 2019 representing a decline of 8% (6% in local currencies) compared to the same period last year. The decline was expected and a result of generic [...]

Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS

08/05/2019 - 07:15

Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent ® (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for [...]

Addex to Present at the 28th Medtech Investing Europe Conference

08/05/2019 - 07:00

Geneva, Switzerland, May 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will give a corporate [...]

IBA Déclaration Intermédiaire – Premier Trimestre 2019

08/05/2019 - 07:00

Louvain-la-Neuve, Belgique, le 8 mai 2019 - IBA (Ion Beam Applications S.A.), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, publie aujourd’hui une revue de ses activités au [...]

IBA BUSINESS UPDATE – FIRST QUARTER 2019

08/05/2019 - 07:00

Louvain-La-Neuve, Belgium, 8 May 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its business update for the first [...]

MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom

08/05/2019 - 01:00

Dr. Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer, invited speaker at the official launch of Myelopathy.org at The British Parliament House of Lords, shared his thoughts on supporting innovative [...]

TOWER ONE Cease Trade Order Due to Late Financial Statements

08/05/2019 - 02:52

VANCOUVER, British Columbia, May 07, 2019 (GLOBE NEWSWIRE) -- TOWER ONE WIRELESS CORP. (CSE: TO) (OTCQB: TOWTF) (Frankfurt: 1P3N) (“Tower One” or the “Company”) announces that a cease trade order has been issued against [...]

Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program

07/05/2019 - 23:17

Company Release no. 09/2019 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 07 May 2019 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals [...]